Skin Inflammation Clinical Trial
Official title:
35 kDa Hyaluronan Fragment (HA35) Reduces Chronic Skin Inflammation
| NCT number | NCT06387212 |
| Other study ID # | HUI0001 |
| Secondary ID | |
| Status | Recruiting |
| Phase | N/A |
| First received | |
| Last updated | |
| Start date | April 15, 2024 |
| Est. completion date | May 2024 |
To explore the clinical effect and safety of 35 kDa hyaluronic acid fragment ( HA35 ) combined with negative pressure microneedle technology in improving skin problems.
| Status | Recruiting |
| Enrollment | 20 |
| Est. completion date | May 2024 |
| Est. primary completion date | May 2024 |
| Accepts healthy volunteers | Accepts Healthy Volunteers |
| Gender | All |
| Age group | 18 Years to 65 Years |
| Eligibility | Inclusion Criteria: - Skin problems include but are not limited to dry skin, dark skin, and coarse pores. - Chronic skin inflammation, pigmentation, erythema, etc. - Cooperate with the experimental requirements and be able to complete the score independently? Exclusion Criteria: - Pregnant or lactating women. - Suffering from psychological or mental illness. - Life is not regular, overeating. - Hypersensitive to hyaluronic acid, and has a scar constitution. |
| Country | Name | City | State |
|---|---|---|---|
| Mongolia | Nahia Impex LLC | Ulaanbaatar |
| Lead Sponsor | Collaborator |
|---|---|
| Nakhia Impex LLC |
Mongolia,
| Type | Measure | Description | Time frame | Safety issue |
|---|---|---|---|---|
| Primary | A skin dryness scale | The Numerical Rating Scale (NRS) was revised and improved, and the 10-point digital score was used to allow the subjects to self-evaluate the skin effect before and after treatment for 120 minutes and 960 minutes. 0 represents no skin dryness, while 10 represents the worst degree of skin dryness. | 120 minutes and 960 minutes | |
| Primary | A fair or smooth skin scale | The Numerical Rating Scale (NRS) was revised and improved, and the 10-point digital score was used to allow the subjects to self-evaluate the skin effect before and after treatment for 120 minutes and 960 minutes. 0 represents the worse degree of fair or smooth skin, while 10 represents the best degree of fair or smooth skin. | 120 minutes and 960 minutes | |
| Primary | A skin pore size scale | The Numerical Rating Scale (NRS) was revised and improved, and the 10-point digital score was used to allow the subjects to self-evaluate the skin effect before and after treatment for 120 minutes and 960 minutes. 0 represents the best degree of skin pore size, while 10 represents the worst degree of skin pore size. | 120 minutes and 960 minutes | |
| Primary | A inflammatory skin thick hardness scale | The Numerical Rating Scale (NRS) was revised and improved, and the 10-point digital score was used to allow the subjects to self-evaluate the skin effect before and after treatment for 120 minutes and 960 minutes. 0 represents the best degree of inflammatory skin thick hardness, while 10 represents the worst degree of inflammatory skin thick hardness. | 120 minutes and 960 minutes | |
| Primary | An erythema color and area scale | The Numerical Rating Scale (NRS) was revised and improved, and the 10-point digital score was used to allow the subjects to self-evaluate the skin effect before and after treatment for 120 minutes and 960 minutes. 0 represents the best degree of erythema color and area, while 10 represents the worst degree of erythema color and area scale. | 120 minutes and 960 minutes | |
| Secondary | Self-satisfaction evaluation | One week after the end of the treatment, a return visit was conducted to collect the overall satisfaction score of the subjects on the skin treatment. Using the questionnaire (0-10 score) to assess this outcome measure. 0 represents the most dissatisfied, while 10 represents the most satisfied. | 1 week after the end of the treatment |
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Active, not recruiting |
NCT04479514 -
Preventative Skin Care for Children Undergoing Targeted CNS Tumor Therapy
|
Phase 2 | |
| Completed |
NCT03065504 -
Turmeric and Turmeric-containing Tablets and Sebum Production
|
N/A | |
| Recruiting |
NCT05535738 -
Using a Contact Dermatitis Model With Biologic Medications to Study Skin Inflammation
|
Phase 2/Phase 3 | |
| Recruiting |
NCT05277324 -
The Effect of Wearing Facial Masks on Skin Parameters During the COVID-19 Pandemic
|
||
| Completed |
NCT05300542 -
Efficacy Study of a Novel Skin Health Product to Reduce an UVB Induced Erythema
|
N/A | |
| Completed |
NCT05745636 -
Broccoli Seed Extract and Skin Health
|
N/A | |
| Completed |
NCT03192280 -
Skin IaM: An Exploratory Clinical Trial to Evaluate Changes in Skin Appearance, Colour, and/or Texture Following the Induction of a Local Inflammatory Skin Response
|
N/A | |
| Withdrawn |
NCT03976206 -
Very Small Embryonic-like Stem Cells for Facial Skin Antiaging
|
Phase 1/Phase 2 | |
| Completed |
NCT05102604 -
The Effect of Avocado vs. Usual Diet on Skin Aging
|
N/A | |
| Withdrawn |
NCT03862872 -
Effects of Bend Beauty's Anti-Aging Formula on Inflammatory Markers
|
N/A | |
| Completed |
NCT04471896 -
Joovvin' for Your Skin Health Study
|
N/A | |
| Recruiting |
NCT03581747 -
Detection of Skin Epithelial Barrier in Patients With Allergic Skin Disorders
|
||
| Completed |
NCT05517720 -
An Exploratory Investigation of a Novel Skincare Regimen
|
N/A | |
| Completed |
NCT05461456 -
Bioavailability and Tolerability of Fexofenadine Hydrochloride Topical Lotion 1%
|
Phase 1 |